ASTRAZEN — Astrazeneca Pharma India Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹222.68bn
- IN₹217.51bn
- IN₹17.16bn
Annual cashflow statement for Astrazeneca Pharma India, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 1,271 | 830 | 1,341 | 2,195 | 1,564 |
| Depreciation | |||||
| Non-Cash Items | -59.3 | -72.9 | -211 | -220 | 364 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -365 | 81 | -710 | -1,846 | -1,674 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 1,048 | 1,008 | 583 | 279 | 654 |
| Capital Expenditures | -77.1 | -96.2 | -85.2 | -108 | -17.5 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1,807 | 144 | 266 | 325 | 326 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 1,730 | 47.4 | 181 | 217 | 308 |
| Financing Cash Flow Items | -10.9 | -9.5 | -6.3 | -5.2 | -14.6 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -89.7 | -94.6 | -245 | -444 | -656 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2,688 | 961 | 519 | 52.3 | 306 |